Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

Adam Ramsey, OD, shares key takeaways from his EyeCon 2022 presentation, "Advances in industry innovations to improve your practice."

The glaucoma field is on the move with significant innovations in a number of treatment areas. Experts discussed the various technologies at the Optometry Times 2022 EyeCon meeting in Marco Island, Florida.

Optometry Times' EyeCon co-chairs Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, MA, OD, FAAO, reflect on the 2023 EyeConversations keynote address, which covered new technology, artificial intelligence, and an update in pharmacology.

Mile Brujic, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

Lyndon Jones, BSc, PhD, DSc, FCAHS, FCOptom, DipCLP, DipOrth, FAAO, FIACLE, FBCLA , shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

Adam Ramsey, OD, shares key takeaways from his presentation on diversity, equity, and inclusion in you optometry practice, which he presented during EyeCon 2022.

Panel discusses the highs and lows of treating patients with this condition.

The preservative-free, multi-dose contact lens rehydrating drops are expected to hit the market in early 2023.

Your employees are your greatest allies; building a team the right way from the very beginning is the foundation of your success.

Considering safety and efficacy of new drops and the potential impact on your patients.

The FDA granted orphan drug designation to BRM424 (BRIM Biotechnology) to treat neurotrophic keratitis (NK).

The positive 3-month efficacy and safety results from Azura Ophthalmic's Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD) met its co-primary endpoints.

The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.

Consider 2 approaches when fitting patients.

Sean W. Smolenyak, OD, gives a brief overview of presbyopia, including the cause and available treatments.

According to the authors, a patient with bilateral choroid metastases from breast cancer experienced "a dramatic response" after a combination treatment of abemaciclib and fulvestrant.

This acquisition for Alcon means a growing ophthalmic portfolio of commercial products and development pipeline.